Drug resistance in glioblastoma: are persisters the key to therapy?

Abstract

Glioblastoma (GBM) represents the main form of brain tumors in adults, and one of the most aggressive cancers overall. The treatment of GBM is a combination of surgery (when possible), chemotherapy (usually Temozolomide, TMZ) and radiotherapy (RT). However, despite this heavy treatment, GBM invariably recur and the median length of survival following diagnosis is 12 to 15 months, with less than 10% of people surviving longer than five years. GBM is extremely resistant to most treatments because of its heterogeneous nature, which is associated with extreme clonal plasticity and the presence of cancer stem cells, refractory to TMZ- and RT-induced cell death. In this review, we explore the mechanisms by which cancer cells, and especially GBM, can acquire resistance to treatment. We describe and discuss the concept of persister/tolerant cells that precede and/or accompany the acquisition of resistance. Persister/tolerant cells are cancer cells that are not eliminated by treatment(s) because of different mechanisms ranging from dormancy/quiescence to senescence. We discuss the possibility of targeting these mechanisms in new therapeutic regimen.

Keywords

Drug resistance / persisters / tolerance / chromatin remodeling / metabolism / tumor environment

References

[1] Stupp R,van den Bent MJ,Fisher B.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma..N Engl J Med2005;352:987-96

[2] Assaraf YG,Gonçalves AC,Linē A.The multi-factorial nature of clinical multidrug resistance in cancer..Drug Resist Updat2019;46:100645

[3] Yang J,Berx G,Brabletz T.Guidelines and definitions for research on epithelial-mesenchymal transition..Nat Rev Mol Cell Biol2020;21:341-52 PMCID:PMC7250738

[4] Gupta PB,Skibinski A,Kuperwasser C.Phenotypic Plasticity: driver of cancer initiation, progression, and therapy resistance..Cell Stem Cell2019;24:65-78 PMCID:PMC7297507

[5] Marusyk A,Polyak K.Intratumor heterogeneity: the rosetta stone of therapy resistance..Cancer Cell2020;37:471-84 PMCID:PMC7181408

[6] Pastushenko I.EMT transition states during tumor progression and metastasis..Trends Cell Biol2019;29:212-26

[7] Saygin C,Majeti R,Lathia JD.Targeting cancer stemness in the clinic: from hype to hope..Cell Stem Cell2019;24:25-40

[8] Vasan N,Hyman DM.A view on drug resistance in cancer..Nature2019;575:299-309

[9] Fulda S.Cell death-based treatment of glioblastoma..Cell Death Dis2018;9:121 PMCID:PMC5833770

[10] Juin P,Gautier F,Campone M.Decoding and unlocking the BCL-2 dependency of cancer cells..Nat Rev Cancer2013;13:455-65

[11] Brocard E,Lalier L,Paris F.Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling..Oncotarget2015;6:6840-9 PMCID:PMC4466653

[12] Valès S,Biraud M,Bessard A.Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis..EBioMedicine2019;49:172-88 PMCID:PMC6945247

[13] Balaban NQ,Lewis K,Aldridge B.Definitions and guidelines for research on antibiotic persistence..Nat Rev Microbiol2019;17:441-8 PMCID:PMC7136161

[14] Guler GD,Pitti R,Nichols K.Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure..Cancer Cell2017;32:221-37.e13

[15] Ravindran Menon D,Torrano J,Fujita M.Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer..Theranostics2020;10:6261-77 PMCID:PMC7255038

[16] Vallette FM,Lézot F,Cochonneau D.Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer..Biochem Pharmacol2019;162:169-76

[17] Hammerlindl H.Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance..J Cell Commun Signal2018;12:133-41 PMCID:PMC5842196

[18] Ramirez M,Steininger RJ,Roth MA.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells..Nat Commun2016;7:10690 PMCID:PMC4762880

[19] Lewis K.Persister cells..Annu Rev Microbiol2010;64:357-72

[20] Kaldalu N.Slow growth causes bacterial persistence..Sci Signal2019;12:aay1167

[21] Lee SY.Temozolomide resistance in Glioblastoma Multiforme..Genes Dis2016;3:198-210 PMCID:PMC6150109

[22] Danson SJ.Temozolomide: a novel oral alkylating agent..Expert Rev Anticancer Ther2001;1:13-9

[23] Talhaoui I,Tchenio T,Saparbaev MK.Aberrant base excision repair pathway of oxidatively damaged DNA: implications for degenerative diseases..Free Radic Biol Med2017;107:266-77

[24] Karayan-Tapon L,Guilhot J,Fromont G.Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods..J Neurooncol2010;97:311-22

[25] Cartron PF,Debien E,Pouliquen D.Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis..Eur J Cancer2012;48:2431-41

[26] Esteller M,Andion E,Hidalgo OF.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents..N Engl J Med2000;343:1350-4

[27] Hervouet E,Campion L,Menanteau J.Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation..Clin Cancer Res2009;15:3519-29

[28] Christmann M,Horn S,Wiewrodt D.MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma..Int J Cancer2010;127:2106-18

[29] Wiewrodt D,Dreimüller N,Perneczky A.MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome..Int J Cancer2008;122:1391-9

[30] Zhang Y,Gibert M Jr,Wang B.The p53 pathway in glioblastoma..Cancers (Basel)2018;10:297 PMCID:PMC6162501

[31] Belter A,Barciszewska AM.Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions..PLoS One2020;15:e0229534 PMCID:PMC7043761

[32] Dinca EB,Sarkaria JN,Prados MD.p53 small molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts..Cancer Res2008;68:10034-9 PMCID:PMC2987557

[33] He F,Song T,Das M.Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding..Proc Natl Acad Sci U S A2019;116:8859-68 PMCID:PMC6500136

[34] Hegi ME,Gorlia T,de Tribolet N.MGMT gene silencing and benefit from temozolomide in glioblastoma..N Engl J Med2005;352:997-1003

[35] O’Regan CJ,Beausang A,Brett FM.Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol..J Neurooncol2018;137:233-40

[36] Chen X,Gan H,Lee JH.A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma..Nat Commun2018;9:2949 PMCID:PMC6063898

[37] de Souza CF,Malta TM,Morozova O.A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence..Cell Rep2018;23:637-51

[38] Lu C,Wang X,Yin J.DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma..Mol Cancer2020;19:28 PMCID:PMC7011291

[39] Briand J,Bougras-Cartron G,Vallette FM.Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation..Clin Epigenetics2019;11:159 PMCID:PMC6854743

[40] Banelli B,Forlani A,Marubbi D.Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells..Oncotarget2017;8:34896-910 PMCID:PMC5471020

[41] Liau BB,Donohue LK,Flavahan WA.Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance..Cell Stem Cell2017;20:233-46.e7 PMCID:PMC5291795

[42] Wang Z,Wang Y,Cong Z.MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma..Biomed Rep2015;3:543-8 PMCID:PMC4487030

[43] Nadaradjane A,Bougras-Cartron G,Vallette FM.MiR-370-3p is a therapeutic tool in anti-glioblastoma therapy but is not an intratumoral or cell-free circulating biomarker..Mol Ther Nucleic Acids2018;13:642-50 PMCID:PMC6258828

[44] Estaquier J,Vayssiere JL.The mitochondrial pathways of apoptosis..Adv Exp Med Biol2012;942:157-83

[45] Rossin A,Hueber AO.TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity..Cancers (Basel)2019;11:639 PMCID:PMC6563024

[46] Trejo-Solís C,Escamilla-Ramírez Á,Jimenez-Farfan D.Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma..Int J Mol Sci2018;19:3773 PMCID:PMC6320836

[47] Cartron PF,Campone M,Vallette FM.Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme..Cell Death Dis2012;3:e421 PMCID:PMC3542591

[48] Martin S,Oliver L,Perrin P.Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal..J Neurooncol2001;52:129-39

[49] Manero F,Gallenne T,Grée D.The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death..Cancer Res2006;66:2757-64

[50] Gratas C,Rabé M,Vallette FM.Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma..Oncotarget2014;5:2428-35 PMCID:PMC4058016

[51] Chang J,Shao L,Demaria M.Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice..Nat Med2016;22:78-83 PMCID:PMC4762215

[52] Yamaguchi R.Finding a Panacea among combination cancer therapies..Cancer Res.2012;72:18-23 PMCID:PMC3282559

[53] Taylor MA,Ray SK.Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma..Apoptosis2018;23:563-75 PMCID:PMC6193815

[54] Buccarelli M,Pacioni S,D’Alessandris QG.Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis..Cell Death Dis2018;9:841 PMCID:PMC6079099

[55] Pawlowska E,Szatkowska M.An interplay between senescence, apoptosis and autophagy in glioblastoma multiforme - role in pathogenesis and therapeutic perspective..Int J Mol Sci2018;19:889 PMCID:PMC5877750

[56] Ulasov IV,Lesniak MS.Autophagy in glioma cells: an identity crisis with a clinical perspective..Cancer Lett2018;428:139-46

[57] Aasland D,Hauck L,Meyer J.Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-κB..Cancer Res2019;79:99-113

[58] Jeon HY,Ham SW,Kim J.Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype..Tumour Biol2016;37:5857-67

[59] Tomicic MT.Targeting anticancer drug-induced senescence in glioblastoma therapy..Oncotarget2018;9:37466-7 PMCID:PMC6331026

[60] Gammoh N,Puente C,Kang H.Suppression of autophagy impedes glioblastoma development and induces senescence..Autophagy2016;12:1431-9 PMCID:PMC5082770

[61] Tien AC,Bao X,Kim S.A phase 0 trial of Ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- andpharmacokinetic-guided expansion cohort..Clin Cancer Res2019;25:5777-86 PMCID:PMC6863147

[62] Nagy A,Selak MA.Mitochondrial energy metabolism and apoptosis regulation in glioblastoma..Brain Res2015;1595:127-42

[63] Oizel K,Oliver L,Geraldo F.Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity..Clin Cancer Res2017;23:6292-304

[64] Lee JH,Kahng JY,Park JS.Human glioblastoma arises from subventricular zone cells with low-level driver mutations..Nature2018;560:243-7

[65] Zhu Z,Du Y,Ying G.Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis..J Neurochem2018;144:93-104

[66] Singer E,Salomonis N,Soteropoulos P.Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma..Cell Death Dis2015;6:e1601 PMCID:PMC4669764

[67] Lo Dico A,Martelli C,Diceglie C.Intracellular redox-balance involvement in temozolomide resistance-related molecular mechanisms in glioblastoma..Cells2019;8:1315 PMCID:PMC6912456

[68] Michelakis ED,Dromparis P,Haromy A.Metabolic modulation of glioblastoma with dichloroacetate..Sci Transl Med2010;2:31ra34

[69] Morfouace M,Bahut M,Naveilhan P.Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications..J Biol Chem2012;287:33664-74 PMCID:PMC3460464

[70] Morfouace M,Oliver L,Pecqueur C.Control of glioma cell death and differentiation by PKM2-Oct4 interaction..Cell Death Dis2014;5:e1036 PMCID:PMC4040711

[71] Shen L,Chen F,Cai J.RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study..BMC Cancer2015;15:970 PMCID:PMC4682245

[72] Oizel K,Nadaradjane A,Vallette FM.D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH..Cell Death Dis2015;6:e1704 PMCID:PMC4385911

[73] Lin H,Affleck VS,Turnbull DM.Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells..Neuro Oncol2017;19:43-54 PMCID:PMC5193020

[74] Al-Nedawi K,Micallef V,May A.Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells..Nat Cell Biol2008;10:619-24

[75] Corcoran C,O’Brien K,Prencipe M.Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes..PLoS One2012;7:e50999 PMCID:PMC3519481

[76] Challagundla KB,Neviani P,Murtadha M.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy..J Natl Cancer Inst2015;107:djv135 PMCID:PMC4651042

[77] Mao L,Chen WX,Yu DD.Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs..Tumour Biol2016;37:5247-56

[78] Medikonda R,Rahman M,Lim M.A review of Glioblastoma immunotherapy..J Neurooncol2020;

[79] Chauvin C,Perroteau J,Lafrance L.NKG2D controls natural reactivity of Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells..Clin Cancer Res2019;25:7218-28

[80] Sengupta S,Frishman C.Impact of temozolomide on immune response during malignant glioma chemotherapy..Clin Dev Immunol2012;2012:831090 PMCID:PMC3486128

[81] Candolfi M,Wibowo M,Puntel M.Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models..Clin Cancer Res2014;20:1555-65 PMCID:PMC3959570

[82] Karachi A,Mitchell DA.Temozolomide for immunomodulation in the treatment of glioblastoma..Neuro Oncol2018;20:1566-72 PMCID:PMC6231207

[83] Noh H,Yan J,Gabrusiewicz K.Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells..Cancer Lett2018;433:176-85 PMCID:PMC6086585

[84] Fleurence J,Fougeray S,Vermeulen S.Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside..Int J Cancer2020;146:424-38

[85] Karachi A,Dastmalchi F,Huang J.Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition..Neuro Oncol2019;21:730-41 PMCID:PMC6556847

[86] Wei J,Gupta P,Zamler D.Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications..Neuro Oncol2020;22:180-94

[87] Bao S,McLendon RE,Shi Q.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response..Nature2006;444:756-60

[88] Gimple RC,Dixit D.Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer..Genes Dev2019;33:591-609 PMCID:PMC6546059

[89] Aderetti DA,Molenaar RJ.The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma..Biochim Biophys Acta Rev Cancer2018;1869:346-54

[90] Verhaak RG,Purdom E,Qi Y.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1..Cancer Cell2010;17:98-110 PMCID:PMC2818769

[91] Rabé M,Álvarez-Arenas A,Belmonte-Beitia J.Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma..Cell Death Dis2020;11:19 PMCID:PMC6944699

[92] Hoang-Minh LB,Yang C,Dajac K.Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma..EMBO J2018;37:e98772 PMCID:PMC6276884

[93] Quinones A.The multifaceted metabolism of glioblastoma..Adv Exp Med Biol2018;1063:59-72

[94] Dongre A.New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer..Nat Rev Mol Cell Biol2019;20:69-84

[95] Fedele M,Pegoraro S,Manfioletti G.Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma..Int J Mol Sci2019;20:2746 PMCID:PMC6600373

[96] Broekman ML,Abels ER,Krichevsky AM.Multidimensional communication in the microenvirons of glioblastoma..Nat Rev Neurol2018;14:482-95 PMCID:PMC6425928